Hanson & Doremus Investment Management’s Novo Nordisk NVO Stock Holding History

Hanson & Doremus Investment Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Hold	5,000	–	–	0.02%	188
2026 Q1	$184K	Hold	5,000	–	–	0.02%	202
2025 Q4	$254K	Sell	5,000 -286	-5%	-$14.6K	0.03%	172
2025 Q3	$293K	Buy	5,286 +210	+4%	+$12.3K	0.04%	163
2025 Q2	$350K	Hold	5,076	–	–	0.05%	148
2025 Q1	$352K	Hold	5,076	–	–	0.05%	144
2024 Q4	$437K	Buy	5,076 +5,000	+6,579%	+$541K	0.07%	115
2024 Q3	$9K	Hold	76	–	–	﹤0.01%	400
2024 Q2	$11K	Hold	76	–	–	﹤0.01%	404
2024 Q1	$10K	Buy	76 +70	+1,167%	+$8.33K	﹤0.01%	403
2023 Q4	$1K	Buy	+6	New	+$593	﹤0.01%	459

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Hanson & Doremus Investment Management's NVO Position: Q2 2026 in Review

Hanson & Doremus Investment Management held its Novo Nordisk (NVO) position steady in Q2 2026 at 5,000 shares worth $240K. The position accounts for 0.02% of the portfolio, ranked #188.

Hanson & Doremus Investment Management first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $437K in Q4 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Hanson & Doremus Investment Management held 5,000 shares of Novo Nordisk worth $240K as of Q2 2026.
Hanson & Doremus Investment Management left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 0.02% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #188 holding.
Hanson & Doremus Investment Management first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
Hanson & Doremus Investment Management's Novo Nordisk position peaked at $437K in Q4 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.